Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able and willing to give their consent to participate, or who have a legally authorised representative who can give consent on their behalf.
• People who have been diagnosed with multiple myeloma (MM) that requires whole-body (systemic) treatment, according to recognised international guidelines.
• People who have recently started a treatment called HyQvia — either no more than 30 days before joining the study or having received no more than 2 doses — or people who are expected to start HyQvia within 30 days after the enrolment visit.
• People who were 18 years of age or older at the time their multiple myeloma was diagnosed.
• People who have available medical records going back to when their multiple myeloma was first diagnosed and treatment was needed.
• People whose doctor estimates they have a life expectancy of more than 6 months at the time of joining the study.
• People whose general health and ability to carry out daily activities falls within a certain range, as measured by a standard medical scoring tool (confirm with trial site).
• People who are willing and able to follow all the requirements set out in the study plan.

Who may not be able to join:

• People who are known to have an allergic reaction or sensitivity to any ingredient in HyQvia.
• People who have a primary immune deficiency condition, or who have been diagnosed with HIV/AIDS, active hepatitis C, or active hepatitis B.
• People who have used immunoglobulin (Ig) therapy or prevention treatment within the 3 months before joining the study.
• People who have a serious infection that requires intravenous (drip) antibiotics at the time of joining — though people taking a short course of antibiotic tablets may still be eligible (confirm with trial site).
• People who have taken part in another clinical trial involving a medicine or medical device within the 30 days before joining, or who plan to do so during this study. Note: people receiving investigational CAR-T cell therapies or bispecific antibody treatments may still be eligible (confirm with trial site).
• People who have a stem cell transplant planned during the study period, or who have previously had a certain type of stem cell transplant — specifically, a transplant using donor cells at any point in the past, or a transplant using their own cells within 3 months before joining.
• People who have had another cancer (other than multiple myeloma) within the 3 years before joining — with some exceptions for certain early-stage or low-risk skin, cervical, breast, or prostate conditions (confirm with trial site).
• People who have had major surgery within 2 weeks before joining, who have not fully recovered from a previous surgery, or who have major surgery planned during the study period. Note: minor procedures under local anaesthetic, and certain spinal procedures, are not considered major surgery (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.